Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
7 Dirt-Cheap Stocks Sitting in the Sweet Spot
02:25pm, Thursday, 23'rd Mar 2023
While it's always nice to get a discount, with cheap stocks, it may be better to go for enterprises sitting in the sweet spot; that is, publicly traded securities that are cheap but not too cheap wher
The Top 7 Growth Stocks in Biotech
06:57pm, Friday, 03'rd Mar 2023
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q4 Earnings and Revenue Estimates
12:48pm, Tuesday, 28'th Feb 2023
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 125% and 31.18%, respectively, for the quarter ended December 2022.
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023
04:01pm, Monday, 27'th Feb 2023
HAMILTON, Bermuda, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at
Kiniksa: Steady Progress With Arcalyst, But Still Pretty Unexciting
08:28am, Sunday, 19'th Feb 2023
Kiniksa did very well with arcalyst, buying low, selling well. However, its pipeline does not excite investors.
Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
04:01pm, Tuesday, 03'rd Jan 2023
HAMILTON, Bermuda, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday,
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference
04:01pm, Wednesday, 30'th Nov 2022
HAMILTON, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Bank of America Securities
Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx Conference
04:01pm, Wednesday, 23'rd Nov 2022
HAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual He
Are Medical Stocks Lagging Kiniksa Pharmaceuticals (KNSA) This Year?
11:17am, Thursday, 10'th Nov 2022
Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Assertio (ASRT) have performed compared to their sector so far this year.
Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's Why
11:37am, Monday, 07'th Nov 2022
Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q3 2022 Earnings Call Transcript
02:45pm, Tuesday, 01'st Nov 2022
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Rachel Frank – Head-Investor Relations Sanj K.
Kiniksa Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 1, 2022
04:01pm, Monday, 31'st Oct 2022
HAMILTON, Bermuda, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, November 1, 2022, at
What Makes Kiniksa Pharmaceuticals, Ltd. (KNSA) a Good Fit for "Trend Investing"
12:50pm, Wednesday, 05'th Oct 2022 Zacks Investment Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks tha
What Makes Kiniksa Pharmaceuticals, Ltd. (KNSA) a Good Fit for "Trend Investing"
10:32am, Wednesday, 05'th Oct 2022
Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Upgraded to Buy: Here's Why
04:00pm, Wednesday, 21'st Sep 2022 Zacks Investment Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
